Leo's Tralokinumab Poised For US Launch In 2021

 
• By Jessica Merrill

The dermatology specialist said a BLA for the IL-13 blocker has been accepted by the US FDA for the treatment of atopic dermatitis.

SC2007_Second Place_1457882090_1200.jpg
Leo's tralokinumab is poised to be the second biologic to market for atopic dermatitis • Source: Shutterstock

More from Dermatological

More from Therapy Areas